BridgeBio Q1: $36.7M Attruby revenue, net loss $167.4M, pipeline advances

BridgeBio Pharma, Inc.

2025-Q1 EPS reported -$0.88 revenue$116,633,000

First full quarter of Attruby net product revenue $36.7M; 2,072 prescriptions from 756 prescribers since Nov 2024 FDA approval.
Net loss attributable to common stockholders $167.4M ($0.88 EPS) vs $35.2M ($0.20) YoY; total revenue $116.6M vs $211.1M.
Cash $540.6M at March 31, 2025; expects $105M milestone payments in Q2 for ex-U.S. BEYONTTRA approvals.
Phase 2 encaleret in hypoparathyroidism: 78% of 9 patients achieved normal blood & urine calcium within 5 days.
Priced $500M 1.75% convertible notes due 2031; used $459M to repay term loan; Thomas Trimarchi appointed President/CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.